中国药物警戒 ›› 2021, Vol. 18 ›› Issue (4): 346-351.
DOI: 10.19803/j.1672-8629.2021.04.11

• 基础研究 • 上一篇    下一篇

蒲地蓝消炎口服液联合阿莫西林对肺炎链球菌感染的协同作用

时宇静, 鲍岩岩, 郭姗姗, 孙静, 赵荣华, 包蕾, 耿子涵, 姚荣妹, 高英杰, 崔晓兰*   

  1. 中国中医科学院中药研究所,北京 100700
  • 收稿日期:2020-10-14 出版日期:2021-04-15 发布日期:2021-04-23
  • 通讯作者: *崔晓兰,女,博士,研究员,中药抗感染药效机制研究。E-mail: cuixiaolan2812@126.com
  • 作者简介:时宇静,女,博士,副研究员·硕导,中药防治感染性疾病药效机制研究。
  • 基金资助:
    国家重大新药创制科技重大专项资金资助（2019ZX09721001-005-001）; 中央级公益性科研院所基本科研业务费专项资金资助（ZZ10-018-09, ZXKT17052）

Synergistic Effect of Pudilan Xiaoyan Oral Liquid Combined with Amoxicillin against Streptococcus Pneumoniae Infection

SHI Yujing, BAO Yanyan, GUO Shanshan, SUN Jing, ZHAO Ronghua, BAO Lei, GENG Zihan, YAO Rongmei, GAO Yingjie, CUI Xiaolan*   

  1. 1Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
  • Received:2020-10-14 Online:2021-04-15 Published:2021-04-23

PDF (PC)

109

摘要： 目的 阿莫西林（amoxicillin, Amx）具有广谱抗菌作用,蒲地蓝消炎口服液（PDL）具有抗炎、免疫调节和抗菌活性。为了增强抗菌药效、减少Amx的不良反应,本研究对二者联合应用的抗肺炎链球菌感染效果进行了研究。方法 以肺炎链球菌滴鼻感染ICR小鼠建立小鼠细菌性肺炎模型;以肺指数、肺组织病理评分、炎症因子表达等作为评价指标,考察PDL和Amx联用对肺炎链球菌感染小鼠肺炎的保护作用。结果 PDL液和Amx联用能显著抑制肺炎链球菌引起的小鼠肺炎病变,两药联用对感染小鼠具有协同抗感染作用,其中Amx（每日0.37 g/kg）与PDL（每日5.5 mL/kg）联用的联合指数为0.12,对肺炎的治疗表现为强协同作用,肺指数抑制率达到61.22%,肺指数显著低于模型对照组和单一药物组（P<0.05,P<0.01）;Amx（每日0.37 g/kg）与PDL（每日2.75 mL/kg）联用的联合指数为0.57,为协同作用。两药联用能显著抑制感染小鼠体重下降,改善小鼠肺组织病理损伤（P<0.01）,同时显著抑制细菌感染诱导的小鼠血清炎症因子白细胞介素-6（IL-6）（P<0.01）、白细胞介素-8小鼠同源物（KC）（P<0.05）、肿瘤坏死因子-α（TNF-α）（ P<0.01）、单核细胞趋化蛋白-1（MCP-1）（P<0.01）的表达升高。结论 PDL和Amx联用对肺炎链球菌感染小鼠肺炎具有协同治疗作用,在临床上具有重要的应用价值。

关键词: 蒲地蓝消炎口服液, 阿莫西林, 肺炎链球菌, 协同作用

Abstract: Objective To study the synergistic effect of amoxicillin combined with Pudilan Xiaoyan oral liquid against Streptococcus pneumoniae infection. Methods ICR mice were intranasally infected with Streptococcus pneumoniae. The protective effect of amoxicillin combined with Pudilan Xiaoyan oral liquid against Streptococcus pneumoniae infection in mice was investigated by using lung indexes, lung tissue pathological scores and expressions of inflammatory factors as evaluation indexes. Results Amoxicillin combined with Pudilan Xiaoyan oral liquid could significantly inhibit the pneumonia induced by Streptococcus pneumoniae in mice. The combination index of amoxicillin (0.37 g·kg-1·d-1) and Pudilan Xiaoyan oral liquid (5.5 mL/kg-1·d-1) was 0.12, which indicated strong synergistic effect on infected mice. The lung index inhibition rate was 61.22%, and the lung index of the combination group was significantly lower than that of the model control group and the single drug group (P<0.05, P<0.01). The combination index of amoxicillin (0.37 g/kg-1·dd-1) and Pudilan Xiaoyan oral liquid (2.75 mL/kg-1·d-1) was 0.57, which indicated the synergistic effect on infected mice. The combination of the two drugs could significantly inhibit the weight loss of infected mice, ameliorate the pathological damage to lung tissue (P<0.01), and significantly inhibit the increase of serum inflammatory factors IL-6 (P<0.01), KC (P<0.05), TNF-α (P<0.01) and MCP-1 (P<0.01) induced by bacterial infection. Conclusion Amoxicillin combined with Pudilan Xiaoyan oral liquid can have synergistic therapeutic effect against pneumonia in mice infected with Streptococcus pneumoniae, which indicates the clinical applicability of this approach.

Key words: Pudilan Xiaoyan oral liquid, amoxicillin, Streptococcus pneumoniae, synergistic effect

中图分类号: